Mercados españoles cerrados

Ono Pharmaceutical Co., Ltd. (OPHLF)

Other OTC - Other OTC Precio demorado. Divisa en USD
Añadir a la lista de favoritos
18,170,00 (0,00%)
A partir del 03:37PM EST. Mercado abierto.

Ono Pharmaceutical Co., Ltd.

8-2, Kyutaromachi 1-chome
Osaka 541-8564
81 6 6263 5670

SectorDrug Manufacturers - General
Empleados a tiempo completo3761

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Gyo SagaraCEO, President & Representative Director935,57kN/A1958
Mr. Masaki ItoCorp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. TaxN/AN/AN/A
Takehiro YamadaCorporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion OfficeN/AN/AN/A
Masayuki TanigawaCorporate Officer & Executive Director of Corporate Development & StrategyN/AN/AN/A
Mr. Toichi Takino Ph.D.Senior Managing Executive Officer, Head of Research Division & DirectorN/AN/A1968
Mr. Toshihiro TsujinakaSr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and DirectorN/AN/A1964
Hiromu Habashita Ph.D.Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of ImmunologyN/AN/AN/A
Kiyoaki IdemitsuManaging Executive Officer, GM of Development Division & DirectorN/AN/A1964
Shinji Takai M.D., Ph.D.Corporate Officer & Head of Medical AffairsN/AN/AN/A
Satoshi TakahagiCorporate Officer and Executive Director of Sales, Marketing & Primary Care Business DivisionN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; and a research collaboration with Turbine Ltd. to identify and validate novel oncology targets. The company was founded in 1717 and is headquartered in Osaka, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Ono Pharmaceutical Co., Ltd., a día 1 de diciembre de 2023, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 4; Derechos de los accionistas: 2; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.